Skip to main content
. 2019 Nov 12;25(3):393–402. doi: 10.1007/s10741-019-09879-x

Table 2.

Renal endpoints for PARADIGM-HF trial; modified and adapted version [20]

graphic file with name 10741_2019_9879_Tab2_HTML.jpg

ACEI angiotensin-converting enzyme inhibitor (enalapril), ARNI angiotensin receptor/neprilysin inhibitor (sacubitril/valsartan), eGFR estimated glomerular filtration rate